Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on December 9, 2019. The filing serves as a voluntary disclosure regarding the "Aytu Transaction," an asset purchase agreement entered into on October 10, 2019, and closed on November 1, 2019, with Aytu BioScience, Inc.
The transaction involves the sale of Cerecor's Pediatric Portfolio assets, including Aciphex Sprinkle, Cefaclor for Oral Suspension, Karbinal ER, Flexichamber, Poly-Vi-Flor, and Tri-Vi-Flor, along with associated commercial infrastructure and sales force employment rights.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains unaudited pro forma condensed combined financial statements illustrating the effects of the Aytu Transaction. These statements include:
- A pro forma condensed combined balance sheet as of September 30, 2019.
- A pro forma condensed combined statement of operations for the year ended December 31, 2018.
- A pro forma condensed combined statement of operations for the nine months ended September 30, 2019.
Investors must refer to the attached Exhibit 99.1 and the Company's Annual Report on Form 10-K for the year ended December 31, 2018, for specific financial data.
Material Changes
The primary material change disclosed is the divestiture of the Company's Pediatric Portfolio. This transaction fundamentally alters the Company's asset base and commercial operations by removing the specified pediatric products and the associated sales infrastructure.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the context of the transaction. The document explicitly states that the pro forma financial statements should be read in conjunction with prior filings (Form 10-K and Form 10-Q) to understand the full financial picture.
Investor Verification Checklist
- Verify the specific financial impact of the Aytu Transaction by reviewing Exhibit 99.1 (unaudited pro forma financial statements) attached to this filing.
- Confirm the exact assets and commercial contracts transferred to Aytu BioScience, Inc. as listed in the asset purchase agreement.
- Review the Company's Form 10-K for the year ended December 31, 2018, to compare historical performance against the pro forma results.
- Check subsequent filings for updates on the integration of the remaining business operations post-transaction.